TY - JOUR
T1 - Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency
AU - Baker, Joshua
AU - Hitchins, Lauren
AU - Vucko, Erika
AU - Havens, Kirsten
AU - Becker, Karen
AU - Arduini, Katherine
N1 - Funding Information:
This paper is part of a Supplement supported by Horizon Therapeutics.
Publisher Copyright:
© 2022 The Authors
PY - 2022/12
Y1 - 2022/12
N2 - We report on a family with ornithine transcarbamylase (OTC) deficiency, an X-linked urea cycle disorder, with variable disease severity and tailored management strategies based on each family member's biochemical profile and clinical presentation. Our primary patient is a female monozygotic twin who presented to medical care at 10 months of age with acute liver failure, gastrointestinal symptoms, altered mental status, hypoglycemia, and hyperammonemia. The patient's older brother, known to have hemizygous OTC deficiency, died at 8 months of age from cardiac arrest after complications secondary to his diagnosis. Despite her family history, manifestation of symptoms of heterozygous (partial) OTC deficiency went unrecognized by multiple providers based on misconceptions regarding a female's risk for X-linked disease. Despite barriers related to the family's low socioeconomic status, follow-up care by a multidisciplinary metabolic care team, including moderate protein restriction and nitrogen scavenger therapy, led to positive outcomes for the patient. Her twin sister and mother are also heterozygous for variants in OTC and remain controlled on moderate protein restriction. This case illustrates the importance of genotyping all individuals with genetic risk factors for OTC deficiency and the variability in disease manifestation that necessitates tailored treatment approaches for individuals with partial OTC deficiency.
AB - We report on a family with ornithine transcarbamylase (OTC) deficiency, an X-linked urea cycle disorder, with variable disease severity and tailored management strategies based on each family member's biochemical profile and clinical presentation. Our primary patient is a female monozygotic twin who presented to medical care at 10 months of age with acute liver failure, gastrointestinal symptoms, altered mental status, hypoglycemia, and hyperammonemia. The patient's older brother, known to have hemizygous OTC deficiency, died at 8 months of age from cardiac arrest after complications secondary to his diagnosis. Despite her family history, manifestation of symptoms of heterozygous (partial) OTC deficiency went unrecognized by multiple providers based on misconceptions regarding a female's risk for X-linked disease. Despite barriers related to the family's low socioeconomic status, follow-up care by a multidisciplinary metabolic care team, including moderate protein restriction and nitrogen scavenger therapy, led to positive outcomes for the patient. Her twin sister and mother are also heterozygous for variants in OTC and remain controlled on moderate protein restriction. This case illustrates the importance of genotyping all individuals with genetic risk factors for OTC deficiency and the variability in disease manifestation that necessitates tailored treatment approaches for individuals with partial OTC deficiency.
KW - Late onset
KW - Manifesting heterozygote
KW - Ornithine transcarbamylase deficiency
KW - Partial ornithine transcarbamylase deficiency
KW - Urea cycle disorder
KW - X-linked
UR - http://www.scopus.com/inward/record.url?scp=85135172769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135172769&partnerID=8YFLogxK
U2 - 10.1016/j.ymgmr.2022.100906
DO - 10.1016/j.ymgmr.2022.100906
M3 - Comment/debate
C2 - 36620388
AN - SCOPUS:85135172769
SN - 2214-4269
VL - 33
JO - Molecular Genetics and Metabolism Reports
JF - Molecular Genetics and Metabolism Reports
M1 - 100906
ER -